These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 10214748

  • 21. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
    Guttman M.
    Neurology; 1997 Oct; 49(4):1060-5. PubMed ID: 9339690
    [Abstract] [Full Text] [Related]

  • 22. Dopamine agonists.
    Factor SA.
    Med Clin North Am; 1999 Mar; 83(2):415-43, vi-vii. PubMed ID: 10093586
    [Abstract] [Full Text] [Related]

  • 23. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [Abstract] [Full Text] [Related]

  • 24. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F, Berardelli A, Vacca L, Thomas A, De Pandis MF, Modugno N, Valente M, Ruggieri S.
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [Abstract] [Full Text] [Related]

  • 25. [Pramipexole in Parkinson disease. Results of a treatment observation].
    Reichmann H, Brecht HM, Kraus PH, Lemke MR.
    Nervenarzt; 2002 Aug; 73(8):745-50. PubMed ID: 12242961
    [Abstract] [Full Text] [Related]

  • 26. The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
    MacMahon DG.
    Age Ageing; 2003 May; 32(3):244-5. PubMed ID: 12720606
    [No Abstract] [Full Text] [Related]

  • 27. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K, Needleman F, Macphee G, Grosset D.
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [Abstract] [Full Text] [Related]

  • 28. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 29. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
    [Abstract] [Full Text] [Related]

  • 30. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M, Samii A, Takkouche B, Rochon PA.
    Drug Saf; 2001 Nov; 24(11):863-8. PubMed ID: 11665873
    [Abstract] [Full Text] [Related]

  • 31. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
    Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH.
    J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):713-20. PubMed ID: 12023411
    [Abstract] [Full Text] [Related]

  • 32. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.
    Holman AJ, Myers RR.
    Arthritis Rheum; 2005 Aug; 52(8):2495-505. PubMed ID: 16052595
    [Abstract] [Full Text] [Related]

  • 33. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K, German Tolcapone Study Group.
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Meco G.
    Funct Neurol; 2002 May; 17(4):199-201. PubMed ID: 12675263
    [Abstract] [Full Text] [Related]

  • 36. Pre-clinical studies of pramipexole: clinical relevance.
    Hubble JP.
    Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S.
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.